BCAA (Branched-Chain Amino Acids)
Also known as: Branched‑chain amino acids, Leucine, Isoleucine, Valine, BCAAs
Meta‑analyses of randomized trials report that BCAA supplementation reduces blood creatine kinase after damaging exercise and can reduce delayed onset muscle soreness in the short term. Individual trials in older or clinical populations using leucine‑enriched BCAA formulas have shown increases in lean mass over 12 weeks; however, functional benefits are not consistently demonstrated and some positive trials are part of multifactorial interventions.
Last reviewed: 2026-10-14 · 5 indexed studies
Set your location for accurate regulatory status
Saved on this device — no sign-in needed.
Overview
Branched‑chain amino acids (leucine, isoleucine and valine) are used orally to reduce markers of exercise‑induced muscle damage and perceived muscle soreness and have been studied for preserving or increasing lean mass in older or clinical populations. Clinical trials and meta‑analyses report modest improvements in some recovery markers and, in specific groups, small increases in muscle mass.
Mechanism & Function
Mechanism of Action
Clinical reports emphasise leucine‑enriched formulations aimed at stimulating muscle anabolism and reducing markers of muscle damage; the included trials use oral BCAA to target post‑exercise recovery and muscle mass in ageing or disease contexts.
Physiological Role
Supplied amino acids are intended to contribute to post‑exercise amino acid availability and to support muscle protein balance in populations with increased need or catabolic stress.
Primary Pathways
Performance / Health Relevance
Evidence supports use for attenuating exercise‑induced muscle damage markers and short‑term muscle soreness; evidence for meaningful improvements in strength or endurance is limited. Some clinical populations show small gains in lean mass with leucine‑enriched formulas over weeks to months.
Evidence Review
Practical Use & Dosage
- Minimum Effective Dose
- Not established from the provided abstracts; one RCT used a leucine‑enriched mix delivering 4.5 g leucine (total BCAA 7.5 g/day).
- Optimal Range
- Not established
- Upper / Caution Level
- Not established
- Timing
- Used around exercise or daily in clinical trials; timing varied by study.
- Best Format
- Oral powder or capsules containing leucine, isoleucine and valine; some trials used leucine‑enriched mixes.
- Bioavailability
- Oral formulations were used in the included trials; details on comparative bioavailability were not provided in the abstracts.
- Absorption Considerations
- Not established in the provided abstracts.
Safety & Interactions
Side Effects
- •Generally well tolerated in the trials provided; no adverse events reported in the cited elderly CKD trial
Monitoring
Monitor clinical response and general tolerance in clinical populations; specific monitoring guidance was not provided in the abstracts.
Frequently Asked Questions
Auto-generated from indexed evidence — dosage, safety, interactions, and more.
When is BCAA (Branched-Chain Amino Acids) typically used or indicated?
BCAA (Branched-Chain Amino Acids) is most commonly used for: Post‑exercise recovery, Attenuation of muscle soreness, Support of muscle mass in older or clinical populations. Supplied amino acids are intended to contribute to post‑exercise amino acid availability and to support muscle protein balance in populations with increased need or catabolic stress.
How does BCAA (Branched-Chain Amino Acids) work?
Clinical reports emphasise leucine‑enriched formulations aimed at stimulating muscle anabolism and reducing markers of muscle damage; the included trials use oral BCAA to target post‑exercise recovery and muscle mass in ageing or disease contexts.
What is the recommended dose of BCAA (Branched-Chain Amino Acids)?
The optimal range is Not established. with a minimum effective dose of Not established from the provided abstracts; one RCT used a leucine‑enriched mix delivering 4.5 g leucine (total BCAA 7.5 g/day).. Best taken: Used around exercise or daily in clinical trials; timing varied by study.. Upper / caution level: Not established.
What are the side effects of BCAA (Branched-Chain Amino Acids)?
Reported side effects include: Generally well tolerated in the trials provided; no adverse events reported in the cited elderly CKD trial. Monitoring: Monitor clinical response and general tolerance in clinical populations; specific monitoring guidance was not provided in the abstracts.
How strong is the evidence for BCAA (Branched-Chain Amino Acids)?
Evidence level: Strong (overall score 76/100), based on 5 indexed studies on SuppIndex.
Research & References (5)
Home exercise, branched-chain amino acids, and probiotics improve frailty in cirrhosis: A randomized clinical trial.
Randomized clinical trial in prefrail and frail outpatients with cirrhosis comparing a 12‑month multifactorial intervention (home exercise, BCAA supplements and multistrain probiotic) versus standard care.
Branched-chain amino acid supplementation and exercise-induced muscle damage in exercise recovery: A meta-analysis of randomized clinical trials.
Meta‑analysis (up to Nov 2015) of randomized trials examining BCAA supplementation and recovery after exercise‑induced muscle damage; eight trials included.
Does Branched-Chain Amino Acids (BCAAs) Supplementation Attenuate Muscle Damage Markers and Soreness after Resistance Exercise in Trained Males? A Meta-Analysis of Randomized Controlled Trials.
Meta‑analysis (2010–2020) of randomized trials in trained males assessing BCAA effects on plasma markers of muscle damage and soreness after resistance exercise; nine studies included.
Effect of branched-Chain Amino Acid Supplementation on Muscle Soreness following Exercise: A Meta-Analysis.
Meta‑analysis of randomized controlled trials assessing effect of BCAA supplementation on delayed onset muscle soreness (DOMS) after acute exercise; eight studies included in primary analysis.
Anti-sarcopenic effect of leucine-enriched branched-chain amino acid supplementation among elderly chronic kidney disease patients: a double-blinded randomized controlled trial.
Double‑blind RCT in elderly chronic kidney disease patients testing oral leucine‑enriched BCAA (60% leucine; 4.5 g leucine, total BCAA 7.5 g/day) versus placebo for 12 weeks.
Related Ingredients
Other top-rated ingredients in Amino Acids.
L-Leucine
82/100Essential BCAA that activates mTORC1 via Sestrin2 sensing, driving phosphorylation of S6K1 and 4E-BP1, initiating cap-dependent translation and muscle protein synthesis.
Beta-Alanine
78/100A rate-limiting precursor to carnosine (β-alanyl-L-histidine) synthesis, enhancing intramuscular pH buffering capacity during high-intensity anaerobic exercise.
EAA Blend
78/100Free-form blend of 9 EAAs (Leu, Ile, Val, Lys, Met, Phe, Thr, Trp, His) at evidence-based ratios; bypasses gastric digestion for rapid plasma aminoacidaemia.
Research Overview
Strong EvidenceCite this ingredient
One-click citation export in APA, MLA, Chicago, BibTeX, or HTML. The URL below is stable and safe to link.
Stable URL
https://thesuppindex.com/ingredients/bcaa-branched-chain-amino-acids
SuppIndex. (2026). BCAA (Branched-Chain Amino Acids): Evidence summary, dosage and clinical studies. Retrieved October 16, 2026, from https://thesuppindex.com/ingredients/bcaa-branched-chain-amino-acids
Based on 5 indexed studies · Evidence level: Strong.
Goal Ratings
Stack Compatibility
Often combined with exercise or other nutritional interventions in trials; multifactorial designs make attribution to BCAA alone difficult.